ONC-392,Pembrolizumab
biontech,Merck
['sclc', 'nsclc', 'biontech']
biontech and oncoc4 present positive phase 1/2 data for antibody candidate bnt316/onc-392 in hard-to-treat nsclc at asco #stocksoftheday #stockalert #stocknews #cancer #phase1/2 #positiveclinicaltrialresults 
Find the most important news and press releases about U.S. publicly-traded companies in real-time and stay ahead of the game!